{"id":2004,"date":"1999-02-01T12:09:00","date_gmt":"1999-02-01T11:09:00","guid":{"rendered":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/monoklonaler-antikoerper-zur-behandlung-des-metastasierten-mammakarzinoms"},"modified":"1999-02-01T12:09:00","modified_gmt":"1999-02-01T11:09:00","slug":"monoklonaler-antikoerper-zur-behandlung-des-metastasierten-mammakarzinoms","status":"publish","type":"post","link":"https:\/\/der-arzneimittelbrief.com\/artikel\/1999\/monoklonaler-antikoerper-zur-behandlung-des-metastasierten-mammakarzinoms","title":{"rendered":"Monoklonaler Antik\u00f6rper zur Behandlung des metastasierten Mammakarzinoms"},"content":{"rendered":"<p>Die verst\u00e4rkte Expression des HER2(Human EGF-related receptor)-Protoonkogens, das einen transmembran\u00e4ren Rezeptor (p185HER2) mit partieller Homologie zum Epidermal growth factor (EGF, Mitogen f\u00fcr Zellen ektodermalen und mesodermalen Ursprungs) kodiert, spielt eine wichtige Rolle in der Pathogenese des Mammakarzinoms. Zahlreiche pr\u00e4klinische Studien Ende der 80er und Anfang der 90er Jahre haben gezeigt, da\u00df monoklonale Antik\u00f6rper; die gegen [&hellip;]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Die verst\u00e4rkte Expression des HER2(Human EGF-related receptor)-Protoonkogens, das einen transmembran\u00e4ren Rezeptor (p185HER2) mit partieller Homologie zum Epidermal growth factor (EGF, Mitogen f\u00fcr Zellen ektodermalen und mesodermalen Ursprungs) kodiert, spielt eine wichtige Rolle in der Pathogenese des Mammakarzinoms. Zahlreiche pr\u00e4klinische Studien Ende der 80er und Anfang der 90er Jahre haben gezeigt, da\u00df monoklonale Antik\u00f6rper; die gegen [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1],"tags":[146,1903,1906,149,1884],"class_list":["post-2004","post","type-post","status-publish","format-standard","hentry","category-allgemein","tag-brustkrebs","tag-her2","tag-human-epidermal-growth-factor-receptor-2","tag-mammakarzinom","tag-trastuzumab"],"_links":{"self":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2004","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/comments?post=2004"}],"version-history":[{"count":0,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/posts\/2004\/revisions"}],"wp:attachment":[{"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/media?parent=2004"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/categories?post=2004"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/der-arzneimittelbrief.com\/api\/wp\/v2\/tags?post=2004"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}